Cargando...
T790M突变的非小细胞肺癌研究现状与前景
Targeted therapy with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) is regarded as the main accepted first-line treatment on EGFR mutation in non-small cell lung cancer (NSCLC). Although targeted therapy for the first and two generation of TKIs may lead to longer progression...
Gardado en:
| Publicado en: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
中国肺癌杂志编辑部
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5973297/ https://ncbi.nlm.nih.gov/pubmed/28302223 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2017.03.09 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|